IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Tarro and Brozzo

Serial No. : 09/125,122

Examiner : Bunner, B.

Filed : January 4, 1999

Group Art Unit: 1647

FOR : PHARMACEUTICAL COMPOSITIONS COMPRISING NATURAL HUMAN ALPHA-INTERFERON

17/B
B.B
5/29/01
(AE)

AMENDMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on May 16, 2001.

Lisa B. Kole
Attorney Name

35,225
Registration No.

Signature

May 16, 2001
Date of Signature

Assistant Commissioner for Patents

Washington, D.C. 20231

SIR:

In response to the Official Action dated December 4, 2001, please consider the following amendments and remarks. Applicants enclose herewith (1) A Petition to Extend Time for a period of three months, up to and including June 4, 2001, together with the required fee for a small entity; (2) a Declaration Under Rule 132 by Dr. Renzo Brozzo, one of the Applicants of the above-identified patent application; and (3) a Notice of Appeal, together with the fee required for a small entity.

AMENDMENTS

IN THE SPECIFICATION:

Please substitute pages 1-12 of the originally filed specification with the pages 1-11 of the substitute specification supplied herewith.

IN THE CLAIMS:

Please delete claims 8, 10, 12, 14, 16 and 18 without prejudice.

Please amend the claims as follows:

B1 subc1

7. (amended) A method of treating a subject having viral hepatitis comprising administering, to the subject, by the peroral route, an oral liquid formulation of natural human α-interferon at a daily dosage of between 100 and 500 IU.

11. (amended) The method of claim 7 wherein the human α-interferon is obtained from lymphocyte cells.

B2

Please add the following new claim:

20. (new) An article of manufacture comprising packaging material and a pharmaceutical agent in liquid formulation within said packaging material, wherein the pharmaceutical agent is therapeutically effective for treating viral hepatitis, and wherein the packaging material comprises a label which indicates that the pharmaceutical agent can be used for treating viral hepatitis and has to be administered through the peroral route at a daily dosage between 100IU and 500 IU, and wherein said pharmaceutical agent is natural human α-interferon.

B3